Shilpa Medicare Limited (SHILPAMED) Q2 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Shilpa Medicare is an integrated pharma company spanning APIs, complex-generic formulations, biologics and CDMO services, with focus on oncology and peptides, coming off its highest-ever quarterly revenue and EBITDA in Q1 FY27. This print will speak to whether the ~30% EBITDA margin holds against raw-material pressure and whether the API capacity ramp-up management guided 'from Q2 FY27' shows up in the numbers.

Shilpa Medicare Limited Q2 Results Date and Time

Per the board-meeting intimation, the Board is scheduled to meet on Thursday, November 5, 2026, to approve the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The trading window remained closed from October 1, 2026 until November 7, 2026 (both days inclusive).

A Q2-FY27 earnings conference call is scheduled for November 5, 2026 at 16:00 hrs IST, following the same-day results. Access is via India dial-in plus international toll-free numbers for the US, UK, Singapore and Hong Kong.

What to expect from Shilpa Medicare Limited's Q2 FY27 results

The quarter tests two things at once: whether the ~30% EBITDA margin guide survives raw-material pressure, and whether the API volume ramp-up from recent capacity increases — which management said would begin 'from Q2 FY27' — is visible in this print.

The external backdrop is mixed but manageable: the rupee was weaker on both the dollar and euro legs through most of July–September (INR-US$ spot at 95.89–95.99 on September 30, 2026 vs 87.71 a year earlier), a translation tailwind for an export-led book where US, Europe and RoW formulations alone contributed Rs. 426 cr of FY26 revenue.

On costs, the index of key APIs and KSMs imported from China was broadly flat sequentially and about 3% lower year on year as of the July preview, suggesting the input-cost impulse stopped intensifying after the 500 bps YoY gross-margin dip to 71% in Q1 FY27. On tariffs, generic pharmaceuticals and their ingredients are explicitly outside the US Section 232 tariff net, and India was listed among 20 jurisdictions eligible for zero-tariff treatment on specified speciality medicines including ADCs.

The base is now steep — revenue moved from Rs. 372 cr in 2QFY26 to Rs. 469 cr in 1QFY27, with Q1 filing revenue of Rs. 465.78 Cr up 44.90% YoY — so the YoY growth rate is likely to moderate even as the API/CDMO ramp and biologics (Rs. 50 cr in Q1, guided to 'significantly higher growth') support the trajectory.

Management has declined specific FY27 numeric guidance but stated confidence in 'delivering a stronger FY27', with the credit rating upgrade from A+ to AA- underscoring the improving balance sheet. The call is also expected to cover the two Japanese late-stage CDMO customers promised earlier under confidentiality.

Key Things To Watch

Guidance scorecard: margin, API ramp and CDMO milestones: The Q1 FY27 concall left several open-ended commitments that this quarter can verify.

• EBITDA margin — guided to 'remain in a similar range' around ~30% — watch whether raw-material pressure pulls the 1QFY27 30% margin below range
• API volume ramp-up from recent capacity increases — guided 'from Q2 FY27', i.e. this quarter; oncology API block completion targeted by end FY27 alongside 15 new oncology API products
• CDMO — ~3 late-stage NCE programs to enter commercial phase by FY27; EU commercial supplies for two new late-stage projects begin 2HFY27; details on two onboarded Japanese customers promised for this call

Biologics and OLC/Unicycive milestones due in FY27

• Aflibercept India commercialization by FY27 with Phase III nearing completion in 1HFY27; rHA Phase 3 start by 1HFY27 (slipped from original FY26); Nivolumab/Pembrolizumab Phase I/III start and partnership signings in FY27; ADC Phase I in FY27 with ADC GMP facility still 'underway' at Q1 FY27 after a Q4FY26 target
• OLC/Unicycive — partner refile guided by Q3 FY27, to be reconciled with management's 'no meaningful contribution in FY27' stance and the prior PDUFA date of June 29, 2026
• Biologics scaling ambition of INR 300-400 crores — watch for quantification as management shifts from 'investment cycle' to 'sweating assets'

Regulatory, legal and one-off overhangs

• FTF Pharma CIRP — NCLT Ahmedabad admitted an insolvency plea citing ~Rs. 2.18 Cr of alleged operational debt on September 9, 2026; impact stated as 'not presently ascertainable' — watch for quantification
• USFDA cadence — Jadcherla re-audit timing pending; Unit VII (Hyderabad) surveillance inspection closed with one procedural observation and CAPA response due; any commercial fallout from the voluntary Class II US recall of 27,923 Pemetrexed vials initiated July 29, 2026
• Gross margin trajectory — 71% in 1QFY27 vs 76% in 1QFY26; whether raw-material pass-through improves, and OERIS final CDSCO marketing authorization status after Subject Expert Committee approval